|
|
|
|
LEADER |
02231 am a22002173u 4500 |
001 |
102629 |
042 |
|
|
|a dc
|
100 |
1 |
0 |
|a Kim, Minlee
|e author
|
100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biological Engineering
|e contributor
|
100 |
1 |
0 |
|a Kogan, Nicole E.
|e contributor
|
700 |
1 |
0 |
|a Kogan, Nicole E.
|e author
|
700 |
1 |
0 |
|a Slack, Frank J.
|e author
|
245 |
0 |
0 |
|a Cis-acting elements in its 3' UTR mediate post-transcriptional regulation of KRAS
|
260 |
|
|
|b Impact Journals/National Center for Biotechnology Information (U.S.),
|c 2016-05-23T17:36:40Z.
|
856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/102629
|
520 |
|
|
|a Multiple RNA-binding proteins and non-coding RNAs, such as microRNAs (miRNAs), are involved in post-transcriptional gene regulation through recognition motifs in the 3' untranslated region (UTR) of their target genes. The KRAS gene encodes a key signaling protein, and its messenger RNA (mRNA) contains an exceptionally long 3' UTR; this suggests that it may be subject to a highly complex set of regulatory processes. However, 3' UTR-dependent regulation of KRAS expression has not been explored in detail. Using extensive deletion and mutational analyses combined with luciferase reporter assays, we have identified inhibitory and stabilizing cis-acting regions within the KRAS 3' UTR that may interact with miRNAs and RNA-binding proteins, such as HuR. Particularly, we have identified an AU-rich 49-nt fragment in the KRAS 3' UTR that is required for KRAS 3' UTR reporter repression. This element contains a miR-185 complementary element, and we show that overexpression of miR-185 represses endogenous KRAS mRNA and protein in vitro. In addition, we have identified another 49-nt fragment that is required to promote KRAS 3' UTR reporter expression. These findings indicate that multiple cis-regulatory motifs in the 3' UTR of KRAS finely modulate its expression, and sequence alterations within a binding motif may disrupt the precise functions of trans-regulatory factors, potentially leading to aberrant KRAS expression.
|
520 |
|
|
|a LUNGevity Foundation
|
520 |
|
|
|a National Institutes of Health (U.S.) (Grant CA157749)
|
546 |
|
|
|a en_US
|
655 |
7 |
|
|a Article
|
773 |
|
|
|t Oncotarget
|